Joanne Wuensch
Stock Analyst
(4.23)
# 3,003
Out of 4,648 analysts
361
Total ratings
62.9%
Success rate
9.85%
Average return
Main Sectors:
Stocks Rated by Joanne Wuensch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLCO Bausch + Lomb | Maintains: Buy | $20 → $24 | $19.97 | +20.18% | 3 | Oct 31, 2024 | |
| SYK Stryker | Maintains: Buy | $406 → $411 | $366.18 | +12.24% | 11 | Oct 31, 2024 | |
| BSX Boston Scientific | Maintains: Buy | $92 → $98 | $84.48 | +16.00% | 32 | Oct 24, 2024 | |
| JNJ Johnson & Johnson | Maintains: Buy | $180 → $185 | $158.46 | +16.75% | 11 | Oct 16, 2024 | |
| NVRO Nevro | Maintains: Neutral | $6.89 → $6 | $5.34 | +12.36% | 18 | Oct 1, 2024 | |
| MDT Medtronic | Maintains: Neutral | $85 → $92 | $89.42 | +2.88% | 18 | Oct 1, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Sell | $20 → $16 | $24.36 | -34.31% | 13 | Oct 1, 2024 | |
| ITGR Integer Holdings | Maintains: Neutral | $124 → $130 | $125.38 | +3.69% | 3 | Oct 1, 2024 | |
| PODD Insulet | Maintains: Buy | $250 → $275 | $236.52 | +16.27% | 12 | Oct 1, 2024 | |
| ESTA Establishment Labs Holdings | Maintains: Neutral | $45 → $50 | $46.60 | +7.30% | 6 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $83 → $77 | $66.72 | +15.41% | 18 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $40 | $35.96 | +11.25% | 19 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $178 → $200 | $228.44 | -12.45% | 23 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $110 | $80.79 | +36.16% | 17 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $512 → $560 | $508.60 | +10.11% | 14 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $85 | $72.22 | +17.70% | 7 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $134 → $120 | $107.68 | +11.44% | 22 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $6.5 | $4.57 | +42.23% | 8 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $130 → $132 | $131.10 | +0.69% | 19 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $40 → $57 | $33.10 | +72.21% | 12 | May 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $88 → $103 | $87.05 | +18.33% | 2 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $148 → $161 | $69.85 | +130.49% | 11 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $116 | $104.85 | +10.63% | 18 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $126 → $128 | $118.25 | +8.25% | 19 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $7.18 | +136.77% | 9 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $220 → $250 | $234.02 | +6.83% | 5 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $67 → $69 | $92.41 | -25.33% | 5 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $109 → $127 | $243.41 | -47.82% | 6 | Dec 10, 2018 |
Bausch + Lomb
Oct 31, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $19.97
Upside: +20.18%
Stryker
Oct 31, 2024
Maintains: Buy
Price Target: $406 → $411
Current: $366.18
Upside: +12.24%
Boston Scientific
Oct 24, 2024
Maintains: Buy
Price Target: $92 → $98
Current: $84.48
Upside: +16.00%
Johnson & Johnson
Oct 16, 2024
Maintains: Buy
Price Target: $180 → $185
Current: $158.46
Upside: +16.75%
Nevro
Oct 1, 2024
Maintains: Neutral
Price Target: $6.89 → $6
Current: $5.34
Upside: +12.36%
Medtronic
Oct 1, 2024
Maintains: Neutral
Price Target: $85 → $92
Current: $89.42
Upside: +2.88%
Integra LifeSciences Holdings
Oct 1, 2024
Maintains: Sell
Price Target: $20 → $16
Current: $24.36
Upside: -34.31%
Integer Holdings
Oct 1, 2024
Maintains: Neutral
Price Target: $124 → $130
Current: $125.38
Upside: +3.69%
Insulet
Oct 1, 2024
Maintains: Buy
Price Target: $250 → $275
Current: $236.52
Upside: +16.27%
Establishment Labs Holdings
Oct 1, 2024
Maintains: Neutral
Price Target: $45 → $50
Current: $46.60
Upside: +7.30%
Oct 1, 2024
Maintains: Buy
Price Target: $83 → $77
Current: $66.72
Upside: +15.41%
Oct 1, 2024
Maintains: Neutral
Price Target: $38 → $40
Current: $35.96
Upside: +11.25%
Aug 22, 2024
Maintains: Neutral
Price Target: $178 → $200
Current: $228.44
Upside: -12.45%
Aug 22, 2024
Maintains: Buy
Price Target: $135 → $110
Current: $80.79
Upside: +36.16%
Aug 22, 2024
Maintains: Buy
Price Target: $512 → $560
Current: $508.60
Upside: +10.11%
Aug 22, 2024
Maintains: Neutral
Price Target: $94 → $85
Current: $72.22
Upside: +17.70%
Jul 10, 2024
Maintains: Neutral
Price Target: $134 → $120
Current: $107.68
Upside: +11.44%
Jul 10, 2024
Maintains: Neutral
Price Target: $6 → $6.5
Current: $4.57
Upside: +42.23%
Jul 10, 2024
Downgrades: Neutral
Price Target: $130 → $132
Current: $131.10
Upside: +0.69%
May 22, 2024
Upgrades: Buy
Price Target: $40 → $57
Current: $33.10
Upside: +72.21%
Apr 3, 2024
Maintains: Buy
Price Target: $88 → $103
Current: $87.05
Upside: +18.33%
Apr 3, 2024
Maintains: Buy
Price Target: $148 → $161
Current: $69.85
Upside: +130.49%
Apr 3, 2024
Maintains: Buy
Price Target: $108 → $116
Current: $104.85
Upside: +10.63%
Apr 3, 2024
Maintains: Buy
Price Target: $126 → $128
Current: $118.25
Upside: +8.25%
Feb 23, 2024
Maintains: Buy
Price Target: $16 → $17
Current: $7.18
Upside: +136.77%
Dec 12, 2022
Upgrades: Neutral
Price Target: $220 → $250
Current: $234.02
Upside: +6.83%
Nov 17, 2022
Maintains: Neutral
Price Target: $67 → $69
Current: $92.41
Upside: -25.33%
Dec 10, 2018
Upgrades: Outperform
Price Target: $109 → $127
Current: $243.41
Upside: -47.82%